MedPath
HSA Approval

DOTAGRAF SOLUTION FOR INJECTION 0.5 MMOL/ML

SIN15973P

DOTAGRAF SOLUTION FOR INJECTION 0.5 MMOL/ML

DOTAGRAF SOLUTION FOR INJECTION 0.5 MMOL/ML

July 6, 2020

BAYER (SOUTH EAST ASIA) PTE LTD

BAYER (SOUTH EAST ASIA) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBAYER (SOUTH EAST ASIA) PTE LTD
Licence HolderBAYER (SOUTH EAST ASIA) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

INTRAVENOUS

Medical Information

V08CA02

gadoteric acid

Manufacturer Information

BAYER (SOUTH EAST ASIA) PTE LTD

Sanochemia Pharmazeutika GmbH

Active Ingredients

gadoterate meglumine eqv gadoteric acid

279.32mg/ml (equivalent to 0.5 mmol/ml)

Gadoteric acid

Documents

Package Inserts

Dotagraf PI.pdf

Approved: January 26, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.